Signals, Powered By EquityPandit
The US health regulator has provided its final approval to the drug firm Jubilant Life Sciences for Celecoxib capsules that are used in treating osteoarthiritis and rheumatoid arthiritis.
Jubilant Life Science has said in a BSE filing that the company “has received Abbreviated New Drug Application (ANDA) final approval for Celecoxib Capsules, 50 mg, 100 mg, 200 mg and 400 mg.”
It added that the company’s product is the generic version of Celebrex of GD Searle that is used in the treatment of osteoarthiritis and rheumatoid arthiritis.
